

PCR-/NAT MRSA / cMRSA (RV 539) Mai 2012



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.
Sample composition and expected results.

	Erwartet / expected	Probenzusammensetzung / Sample composition	
1215391	++	61 / 71,72	cMRSA (<i>S. aureus</i> , oxa ^R , PVL-pos) (~ 1x10 ⁵ CFU/mL)
1215392	Ø	62 / 76	CoNS (oxa ^R) (~ 1x10 ⁴ CFU/mL)
1215393	Ø	62 / 71,72	cMSSA (<i>S. aureus</i> , oxa ^S , PVL-pos) (~ 1x10 ⁵ CFU/mL)
1215394	Ø	62	<i>Escherichia coli</i> K12

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.
Absolute numbers of reported individual results.

n = 228		Probennummer (Sample no.)				Inhibition				
Befund Result		1215391	1215392	1215393	1215394		1215391	1215392	1215393	1215394
Positiv	228	4	3	1		n.d.	0	0	0	0
Negativ	0	222	224	227		nein no	228	227	228	228
Fraglich, Questn.	0	2	1	0		ja, yes	0	1	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden. Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv True positive results			NAT richtig negativ True negative results		
	Absolut Absolute	Relativ Relative	%	Absolut Absolute	Relativ Relative	%
BD GeneOhm MRSA [20] (n=38)	38	38 / 38	100	114	114 / 114	100
GenoType MRSA Direct [21] (n=39)	39	39 / 39	100	115	115 / 117	98
Hyplex StaphyloResist [22] (n=4)	4	4 / 4	100	12	11 / 11 §	100
LightCycler Kits [23] (n=2)	2	2 / 2	100	6	6 / 6	100
GeneXpert (Cepheid) [24] (n=62)	62	62 / 62	100	186	186 / 186	100
LC MRSA Advanced (Roche) [25] (n=28)	28	28 / 28	100	84	84 / 84	100
LightMix MRSA (TIB Molbiol) [26] (n=2)	2	2 / 2	100	6	6 / 6	100
Commercial assay kit [27] (n=15)	15	15 / 15	100	44	44 / 45	98
In house PCR assay [28] (n=43)	43	43 / 43	100	123	123 / 127 §	97
Andere / k.A. / other [29] (n=11)	11	11 / 11	100	32	32 / 33	97

* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.
Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants.
§ Due to reporting questionable results, the number of true results (denominator in the "relative" column) have been reduced.

Comments: 1) A dedicated cMRSA identification (*lukFS* gene detection) was performed by 64 laboratories. All reported results were correct.